Stock screenerAll disclosures →
EDGAR →
IBRX
Conviction 59HealthcareScan · Thu, Jun 25, 2026Dragonfly doji
IBRX$7.78-0.26%
ResistanceSupportVol 14Insider sellVol MA14 12.09M
Mar 26Apr 14May 1May 19Jun 8Jun 25
WSB mentions · 24h changelatest +200.00%· 3 mentions
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price7.78
Change-0.26%
Gap-0.51%
Rel volume1.48×
Avg volume12.51M
Avg $ vol91.16M
SMA 207.26
SMA 507.56
SMA 2005.24
Price vs 50+2.91%
Price vs 200+48.53%
MA stackbullish
50/200 cross—
Supertrenddown · 8.30
RSI (14)56
MACD hist0.09
MACD crossbull · 3d
Stoch %K / %D86 / 81
ADX (14)8
+DI / −DI19 / 16
RSI divergence—
MACD divergenceBullish
ATR %+6.34%
ADR %5.81%
52w high11.55
52w low1.98
From 52w high-32.64%
Above 52w low+292.93%
New 52w highNo
SqueezeOn · 8d
Bollinger width14.98%
%B0.98
Donchian pos77.93%
Donchian high8.09
Donchian low6.69
AVWAP (52w high)8.13
vs AVWAP high-4.31%
AVWAP (52w low)6.72
vs AVWAP low+15.69%
OBV trendDown
Chaikin MF (20)-0.03
Today vs 20d1.48×
Avg vol (14d)12.09M
Avg vol (20d)12.51M
Avg $ vol (20d)91.16M
Market cap8.15B
RS 3m (vs SPY)-7.06%
RS 6m (vs SPY)+267.26%
RS line new highNo
Trend template6/8
Technical rank82.5
1 week+11.30%
1 month-1.77%
3 months-3.59%
6 months+242.73%
1 year+178.85%
YTD+285.15%
P/E-23.19
P/B-9.37
P/S71.93
P/FCF-26.39
EPS-0.3800
Div yield—
ROE40.39%
ROA-54.34%
Debt/Eq-0.00
Current6.67
EV/EBITDA-33.03
Gross margin—
Net margin-310.18%
Rev growth668.31%
EPS growth15.03%
Price target13.00
Target upside67.10%
Analyst ratingBuy
Institutional20.29%
Ent. value7.94B
Revenue44.21M
Net income-632.78M
Gross profit—
Free cash flow-308.78M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out1.05B
Employees691
ListedWed, Mar 10, 2021
Free float368.17M
Float %35.8%
Short interest132.14M
Days to cover7.6d
Short volume61.1%
Squeeze score86 / 100
Next earningsTue, Aug 4, 2026 (40d)
EPS forecast−$0.09 · 2 est
Last EPS vs est−$0.09 vs −$0.08
Last surprise-12.5% miss
Setup gradeC
Conviction59 / 100
Pattern quality—
Tech rank82.5 / 100
Group rank50 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmDragonfly doji
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in IBRX
No recent disclosed trades by Congress in IBRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in IBRX · 6 buys · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Wendel Bruce Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
BLASZYK MICHAEL D Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Cohen Cheryl Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Clark Wesley Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Selecky Christobel Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
MAXWELL LINDA Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Simon Barry J. Director · Common Stock · 2026-06-04 | Sell | 23.03K | $165K | 2026-06-04 | 2026-06-05 |
SEC filings
EDGAR filings in IBRX · 2 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.